NCT03091257 2026-03-13
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1 Active not recruiting
Clinical Trials
266 trialsNCT04579523 2026-03-13
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Not yet recruiting
NCT06348108 2026-03-13
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT06185751 2026-03-11
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Washington University School of Medicine
Phase 1 Recruiting
NCT06623630 2026-03-11
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Washington University School of Medicine
Phase 1 Recruiting
NCT07340853 2026-03-10
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT06203912 2026-03-05
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03070327 2026-03-04
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05887167 2026-03-04
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Cedars-Sinai Medical Center
Phase 1 Recruiting
NCT02291848 2026-02-25
TACTAM
Baylor College of Medicine
Phase 1 Recruiting
NCT05556798 2026-02-24
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT07082270 2026-02-19
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Not yet recruiting
NCT05391750 2026-02-17
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
Emory University
Phase 1 Active not recruiting
NCT07333261 2026-02-13
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
University of Alabama at Birmingham
Phase 1 Recruiting
NCT07407010 2026-02-12
CM336-001
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT04322292 2026-02-11
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT05981209 2026-02-02
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT07377435 2026-01-29
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07333430 2026-01-12
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
Hadassah Medical Organization
Phase 1 Recruiting
NCT04640779 2026-01-06
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Active not recruiting
NCT07093554 2026-01-05
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Recruiting
NCT06042725 2025-12-24
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 1 Recruiting
NCT04077307 2025-12-19
MAATEO
Thomas Helleday Foundation
Phase 1 Recruiting
NCT05775094 2025-12-19
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT07003555 2025-11-26
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Beijing GoBroad Hospital
Phase 1 Recruiting
NCT07003568 2025-11-26
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Beijing GoBroad Hospital
Phase 1 Recruiting
NCT04795882 2025-11-20
MCARTY
University College, London
Phase 1 Recruiting
NCT05065047 2025-11-12
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended
NCT05892393 2025-11-12
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT05139225 2025-11-04
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05411497 2025-11-04
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Active not recruiting
NCT02199665 2025-11-03
SINE
University of Chicago
Phase 1 Completed
NCT05363111 2025-10-29
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
Phase 1 Recruiting
NCT07221032 2025-10-27
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT06270888 2025-10-16
Hypofractionation (Radiation) Trial for Multiple Myeloma
University of Chicago
Phase 1 Recruiting
NCT02315157 2025-10-15
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Thomas Jefferson University
Phase 1 Withdrawn
NCT03017820 2025-10-08
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT07200089 2025-09-30
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT06698744 2025-09-23
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT04555551 2025-09-22
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05823571 2025-09-18
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT06547112 2025-08-29
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
Washington University School of Medicine
Phase 1 Completed
NCT06523699 2025-08-28
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Washington University School of Medicine
Phase 1 Recruiting
NCT05836896 2025-08-24
CARLOTTA01
Technische Universität Dresden
Phase 1 Recruiting
NCT05913804 2025-08-15
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Recruiting
NCT07113496 2025-08-13
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Not yet recruiting
NCT07114432 2025-08-11
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Not yet recruiting
NCT06588660 2025-07-29
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 1 Terminated